Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James Frakes
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 9
- Beta
- 1.40
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -40.46
Financials
Revenue
$0.00-100.0%Net Income
$-1.55MEBITDA
$-1.48MFree Cash Flow
$-1.91BEPS (diluted)
$-4.02Shares Outstanding (diluted)
384.7K+202.8%Operating Expenses
$1.58MCash & Debt
$4.93MReturn of Capital
$0.00Revenue by Segment (annual)
$294.2KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-7.15M | $-10.61 |
| 2025 | $0.00 | $-13.39M | $-85.77 |
| 2024 | $0.00 | $-12.21M | $-388.67 |
| 2023 | $574.2K | $-12.03M | $-468.60 |
| 2022 | $294.2K | $-10.42M | $-564.68 |
| 2021 | $659.1K | $-7.89M | $-521.81 |
| 2020 | $650.2K | $-6.37M | $0.00 |
| 2019 | $229.6K | $-6.20M | $0.00 |
| 2018 | $149.6K | $-5.68M | $0.00 |
| 2017 | $392.1K | $-7.28M | $0.00 |
| 2016 | $886.6K | $-4.87M | $0.00 |
| 2015 | $762.4K | $-6.80M | $0.00 |
| 2014 | $1.62M | $-13.36M | $-516.22 |
| 2013 | $1.23M | $-4.89M | $-245.88 |
Valuation
AEMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·4d ago·Neutral
Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript
View source ↗ - Newsprnewswire.com·19d ago·Neutral
…pected by mid-2027 and Phase 1b and Phase 2b topline data expected in 2028 SAN DIEGO and AUSTIN, Texas, Sept. 17, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD) ("Aethlon" or the "Company") today announced that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with North Immunology, Inc. ("North Immunology"), Nighthawk Merger Sub Corp., a wholly owned subsidiary of Aethlon, and Nighthawk Second Merger Sub, LLC, a wholly owned subsidiary o…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Aethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call Transcript Aethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·53d ago·Neutral
Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program Conference Call Today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-2.91 per share
Typical surprise -21.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-4.02 vs $-3.92miss
- Wed, Jun 10$20.40 vs $-12.30beat
- Thu, Feb 12$-12.25 vs $-10.05miss
- Wed, Nov 12$-18.70 vs $-8.50miss
- Wed, Aug 13$-42.50 vs $-34.00miss
- Thu, Jun 26$-161.00 vs $-4.90miss
Estimates and results for AEMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AEMD officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AEMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.